Kseniya Prudyus is an accomplished health economics and health technology assessment (HTA) professional with expertise in market access, pricing, reimbursement, and evidence generation for innovative therapies. She holds an MSc in International Health Policy & Health Economics from the London School of Economics and Political Science (2019) and a BSc in Biomedical Science from King's College London (2018). Her career has centred on supporting pharmaceutical and biotech clients in navigating complex European HTA and payer landscapes, particularly across the EU5.

From 2021 to 2024, as a Consultant to Senior Consultant at Trinity Life Sciences in London, Kseniya led pricing and market access launch strategies, opportunity assessments, and HTA readiness projects for top-10 pharma companies and early-stage biotechs in oncology, neurology, autoimmune diseases, and rare diseases. She conducted primary payer and KOL research, developed value propositions, and guided evidence generation to optimize reimbursement outcomes. Previously at Oliver Wyman (2020–2021), she performed epidemiological analyses, pipeline evaluations, and built global payer value packs and negotiation tools. During her LSE MSc internship at Bristol-Myers Squibb and subsequent role analysing 20 years of NICE Technology Appraisals (resulting in a BMJ publication), she honed her skills in systematic evidence review, critical appraisal, and understanding real-world HTA decision drivers. Kseniya combines rigorous analytical capabilities with strong stakeholder engagement and strategic insight to advance access for innovative healthcare solutions.